Alyin: Net profit in the first quarter of 2024 was 282 million yuan, a year-on-year decrease of 55.27%

Asymchem (002821) disclosed its first quarter report for 2024 on April 26.
In the first quarter of 2024, the company achieved total operating income of 1.400 billion yuan, a year-on-year decrease of 37.76%; net profit attributable to the parent company was 282 million yuan, a year-on-year decrease of 55.27%; non-net profit after deduction was 254 million yuan, a year-on-year decrease of 58.88%; Net cash flow was 491 million yuan, a year-on-year decrease of 62.36%; during the reporting period, Asymchem\’s basic earnings per share was 0.76 yuan, and the weighted average return on net assets was 1.60%.
In the first quarter of 2024, the company\’s gross profit margin was 43.52%, a decrease of 4.88 percentage points year-on-year; the net profit margin was 19.97%, a decrease of 7.95 percentage points compared with the same period last year.
Data show that the company\’s weighted average return on net assets in the first quarter of 2024 was 1.60%, a decrease of 2.35 percentage points from the same period last year; the company\’s return on invested capital in the first quarter of 2024 was 1.25%, a decrease of 2.49 percentage points from the same period last year. .
In the first quarter of 2024, the company\’s operating income cash ratio was 133.86% and the net cash ratio was 174.01%.
In terms of major changes in assets, as of the end of the first quarter of 2024, the company\’s trading financial assets decreased by 24.71% compared with the end of the previous year, and the proportion of the company\’s total assets decreased by 2.41 percentage points; monetary funds increased by 6.16% from the end of the previous year, and the proportion of the company\’s total assets increased by 2.07 percentage points; accounts receivable decreased by 14.30% from the end of the previous year, and the proportion of the company\’s total assets decreased by 1.48 percentage points; construction in progress increased by 13.82% from the end of the previous year, and the proportion of the company\’s total assets increased by 0.90 percentage points.
In terms of major changes in liabilities, as of the end of the first quarter of 2024, the company\’s employee compensation payable decreased by 48.85% compared with the end of the previous year, accounting for a decrease of 0.74 percentage points in the company\’s total assets; other payables (including interest and dividends) increased by 16.71% compared with the end of the previous year, accounting for The proportion of the company\’s total assets increased by 0.59 percentage points; contract liabilities increased by 22.89% from the end of the previous year, and their proportion to the company\’s total assets increased by 0.25 percentage points; accounts payable decreased by 10.50% from the end of the previous year, and their proportion to the company\’s total assets decreased by 0.24 percentage points.
The first quarter report shows that among the company\’s top ten tradable shareholders at the end of the first quarter of 2024, the new shareholder is HAO HONG, replacing the E Fund CSI 300 Medical and Health Trading Open-End Index Securities Investment Fund at the end of the previous year.
In terms of specific shareholding ratios, ASYMCHEMLABORATORIES, INCORPORATED, HKSCCNOMINEESLIMITED, Hong Kong Securities Clearing Company Limited, Tianjin Guorong Business Information Consulting Co., Ltd., Asymchem Pharmaceutical Group (Tianjin) Co., Ltd.-2022 Employee Stock Ownership Plan, Investment National Certificate The shareholdings of biomedical index tiered securities investment funds have increased, while the shareholdings of China-Europe Medical and Health Hybrid Securities Investment Funds, Hwabao CSI Medical Exchange-traded Open-End Index Securities Investment Funds, and China-Europe Medical Innovation Equity Securities Investment Funds have declined.